RT Journal Article
SR Electronic
T1 Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 30
DO 10.1186/s40425-019-0508-1
VO 7
IS 1
A1 Chung, Hyun Cheol
A1 Arkenau, Hendrik-Tobias
A1 Lee, Jeeyun
A1 Rha, Sun Young
A1 Oh, Do-Youn
A1 Wyrwicz, Lucjan
A1 Kang, Yoon-Koo
A1 Lee, Keun-Wook
A1 Infante, Jeffrey R.
A1 Lee, Sung Sook
A1 Kemeny, Margaret
A1 Keilholz, Ulrich
A1 Melichar, Bohuslav
A1 Mita, Alain
A1 Plummer, Ruth
A1 Smith, Denis
A1 Gelb, Arnold B.
A1 Xiong, Huiling
A1 Hong, Janet
A1 Chand, Vikram
A1 Safran, Howard
YR 2019
UL http://jitc.bmj.com/content/7/1/30.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.